Celldex Therapeutics, Inc. financial data

Symbol
CLDX on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
53 Frontage Road, Suite 220, Hampton, NJ
State of incorporation
Delaware
Fiscal year end
December 31
Former names
AVANT IMMUNOTHERAPEUTICS INC (to 9/29/2008), T CELL SCIENCES INC (to 8/21/1998)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.06K % +12.2%
Debt-to-equity 5.68 % -24.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 66.3M shares +40.3%
Common Stock, Shares, Outstanding 66.3M shares +40.3%
Entity Public Float 1.6B USD +23.1%
Common Stock, Value, Issued 66K USD +40.4%
Weighted Average Number of Shares Outstanding, Basic 66K shares +39.7%
Weighted Average Number of Shares Outstanding, Diluted 66K shares +39.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 8.3M USD +155%
Research and Development Expense 136M USD +39.8%
General and Administrative Expense 35.3M USD +30.7%
Costs and Expenses 184M USD +47.9%
Operating Income (Loss) -176M USD -45%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -112M USD -58.8%
Earnings Per Share, Basic -2.75 USD/shares -14.1%
Earnings Per Share, Diluted -2.75 USD/shares -14.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 42.7M USD +51.4%
Marketable Securities, Current 760M USD +238%
Assets, Current 812M USD +207%
Property, Plant and Equipment, Net 3.86M USD -1.88%
Operating Lease, Right-of-Use Asset 2.45M USD -24.8%
Intangible Assets, Net (Excluding Goodwill) 27.2M USD 0%
Other Assets, Noncurrent 107K USD 0%
Assets 846M USD +183%
Accounts Payable, Current 3.8M USD +332%
Employee-related Liabilities, Current 9.35M USD +24.2%
Accrued Liabilities, Current 18.6M USD +51.7%
Liabilities, Current 27.7M USD +76.8%
Operating Lease, Liability, Noncurrent 796K USD -53.9%
Other Liabilities, Noncurrent 3.47M USD -21.1%
Liabilities 31.9M USD +46.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.78M USD -14.1%
Retained Earnings (Accumulated Deficit) -1.47B USD -11.4%
Stockholders' Equity Attributable to Parent 814M USD +193%
Liabilities and Equity 846M USD +183%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -40.6M USD -42.2%
Net Cash Provided by (Used in) Financing Activities 436M USD +62740%
Net Cash Provided by (Used in) Investing Activities -315M USD -700%
Common Stock, Shares Authorized 297M shares 0%
Common Stock, Shares, Issued 66.3M shares +40.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 80.3M USD +225%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 42.7M USD +51.4%
Deferred Tax Assets, Valuation Allowance 347M USD +11.1%
Deferred Tax Assets, Gross 353M USD +10.9%
Operating Lease, Liability 2.54M USD -37%
Payments to Acquire Property, Plant, and Equipment 344K USD -41.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -151M USD -36%
Lessee, Operating Lease, Liability, to be Paid 2.74M USD -39.8%
Property, Plant and Equipment, Gross 26.4M USD +4.23%
Operating Lease, Liability, Current 1.59M USD +3.86%
Lessee, Operating Lease, Liability, to be Paid, Year Two 949K USD -49.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.79M USD +0.68%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 195K USD -62.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 896K USD +1127%
Deferred Tax Assets, Operating Loss Carryforwards 198M USD +4.97%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 3M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 775K USD +6.75%
Share-based Payment Arrangement, Expense 29.2M USD +57.2%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%